Literature DB >> 11769818

Determining the optimal dose of haloperidol in first-episode psychosis.

P Oosthuizen1, R A Emsley, J Turner, N Keyter.   

Abstract

Uncertainty exists as to the most appropriate dose of haloperidol in first-episode psychosis. This study set out to determine whether ultra-low doses of haloperidol could successfully treat patients with first-episode psychosis. Thirty-five patients with a first episode of psychosis were treated with haloperidol in an open label, fixed protocol over a 12-week period with doses restricted to 1 mg per day for the first 4 weeks. Twenty-nine (83%) remained on haloperidol after 12 weeks at a mean dose of 1.78 mg per day, 16 (55%) had stabilized on 1 mg/day or less. The mean percentage reduction in Positive and Negative Symptom Scale score between baseline and 6 and 12 weeks was 30.3% (SD 20.9%) and 41.4% (SD 16.6%), respectively. There were no significant differences in mean extrapyramidal symptom ratings between baseline and 12 weeks. Ultra-low doses of haloperidol are effective and well tolerated in first-episode psychosis. Initial doses should be maintained for a sufficient period of time to allow for the medication to take full effect.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11769818     DOI: 10.1177/026988110101500403

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  12 in total

Review 1.  First-episode schizophrenia: a focus on pharmacological treatment and safety considerations.

Authors:  Deanna L Kelly; Robert R Conley; William T Carpenter
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  The relationships between depression and remission in first-episode psychosis.

Authors:  Piet Oosthuizen; Robin Emsley; Dana Niehaus; Liezl Koen; Bonga Chiliza
Journal:  World Psychiatry       Date:  2006-10       Impact factor: 49.548

3.  Visualization and Non-Destructive Quantification of Inkjet-Printed Pharmaceuticals on Different Substrates Using Raman Spectroscopy and Raman Chemical Imaging.

Authors:  Magnus Edinger; Daniel Bar-Shalom; Jukka Rantanen; Natalja Genina
Journal:  Pharm Res       Date:  2017-03-01       Impact factor: 4.200

4.  Diagnostic Difficulties and Treatment Challenges of a Young Patient With Severe Acute Psychosis and Complete Recovery.

Authors:  Jagoda Siembida; Saaduddin Mohammed; Mariam Chishty; Luba Leontieva
Journal:  Cureus       Date:  2022-04-01

Review 5.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Authors:  Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

6.  Antipsychotic Medication in Sub-Saharan Africa: A Systematic Literature Review.

Authors:  Sanjana Kumar; Shwetha Sudhakar; Martha Sajatovic; Jennifer B Levin
Journal:  J Clin Psychopharmacol       Date:  2020 Nov/Dec       Impact factor: 3.153

7.  A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse.

Authors:  Mark Abie Horowitz; Sameer Jauhar; Sridhar Natesan; Robin M Murray; David Taylor
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 7.348

8.  Drug utilization study of psychotropic drugs in outdoor patients in a teaching hospital.

Authors:  K G Piparva; D M Parmar; A P Singh; M V Gajera; H R Trivedi
Journal:  Indian J Psychol Med       Date:  2011-01

Review 9.  Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review.

Authors:  Benedicto Crespo-Facorro; Jose Maria Pelayo-Teran; Jacqueline Mayoral-van Son
Journal:  Neurol Ther       Date:  2016-08-23

10.  Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns.

Authors:  Rogelio Apiquian; Ana Fresán; Camilo de la Fuente-Sandoval; Rosa-Elena Ulloa; Humberto Nicolini
Journal:  BMC Psychiatry       Date:  2004-04-27       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.